Sector Expert: Rohit Vanjani

Oppenheimer & Co.

Image: Rohit Vanjani

Rohit Vanjani is executive director and senior analyst covering generics and specialty pharmaceuticals at Oppenheimer & Co. He has been with the firm since 2011, initially working on the Healthcare Services Team (healthcare IT, PBMs, and labs). Prior to Oppenheimer, Vanjani worked at Jefferies, UBS, and Leerink Swann, helping to cover the biotechnology, managed care and hospitals, and specialty pharmaceuticals verticals. He has also worked as an assistant economist at the Federal Reserve Bank of New York and as an economics associate at Stanford University, helping to conduct healthcare economic research. Prior to those roles, Vanjani worked as a laboratory associate researching enzyme active site residues and animal mitochondrial DNA. He holds a bachelor's degree in biochemistry and economics from the University of Michigan, and a master's degree in business administration from New York University's Stern School of Business.



Recent Quotes

"OPK anticipates a ~three-fold increase in Claros 1 cassette production."

— Rohit Vanjani, Oppenheimer & Co. (6/4/14)
more >

"OPK's 4Kscore Test will actually save the system a lot of money, and can better analyze for prostate cancer."

The Life Sciences Report Interview with Rohit Vanjani (5/22/14)
more >

"We believe OPK's 4Kscore will serve as a better guide for physicians in assessing high-grade prostate cancer."

— Rohit Vanjani, Oppenheimer & Co. (5/16/14)
more >

"Investors are undervaluing OPK's 4Kscore opportunity."

— Rohit Vanjani, Oppenheimer & Co. (5/12/14)
more >

"We are initiating coverage of OPK with an Outperform rating; the diagnostic products represent the nearest-term opportunity."

— Rohit Vanjani, Oppenheimer & Co. (3/13/14)
more >



Due to permission requirements, not all quotes are shown.